Shaalan Beg
Assistant Professor · University of Texas Southwestern Medical Center
Credentials: · · · · · ·
History
Research
Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours
British Journal of Cancer · 2020 · Last of 23 authors · 796 citations
Investigational New Drugs · 2017 · First of 10 authors · Corresponding · 719 citations
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline
Journal of Clinical Oncology · 2020 · 478 citations
19 papers · 14 as a resident
19 papers · 2 as a resident
15 papers
- AS
12 papers
12 papers
12 papers
10 papers · 4 as a resident
9 papers
Grants
- 2010–2026
UT Southwestern Medical Center Simmons Comprehensive Cancer Center
National Cancer Institute · P30
Project lead · $1.7M · Ut Southwestern Medical Center
Clinical trials
- 2019–2022
Biological Effect of Warfarin on Pancreatic Cancer
Principal investigator · Withdrawn · Early phase 1
University of Texas Southwestern Medical Center
- 2016–2020
LEE001 and Chemoembolization In Patients With Advanced Hepatocellular Carcinoma
Principal investigator · Terminated · Phase 2
University of Texas Southwestern Medical Center
- 2016–2022
ARQ-761 Treatment With Gemcitabine/Nab-Paclitaxel Chemotherapy In Pancreatic Cancer
Principal investigator · Terminated · Phase 1
University of Texas Southwestern Medical Center
- 2015–2017
Principal investigator · Completed
University of Texas Southwestern Medical Center